Portfolio Holdings Detail for ISIN IE00BYXG2H39

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE

Holdings detail for YMAB

Show aggregate YMAB holdings

News associated with YMAB

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Sees Large Decrease in Short Interest

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) saw a large drop in short interest in the month of August. As of August 15th, there was short interest totaling 1,660,000 shares, adropof25.6% from the July 31st total of 2,230,000 shares. Approximately4.8% of the company’s shares are sold short. Based on an average daily trading volume, […] - 2025-09-09 02:57:07

Head-To-Head Contrast: Y-mAbs Therapeutics (NASDAQ:YMAB) & Viridian Therapeutics (NASDAQ:VRDN)

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership. Earnings & Valuation This table compares Y-mAbs […] - 2025-08-21 05:13:04

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $15.60 Average PT from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, seven have issued a buy recommendation and two have given a strong […] - 2025-08-01 03:08:59

Alps Advisors Inc. Sells 2,906 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Alps Advisors Inc. lowered its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 8.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 33,309 shares of the company’s stock after selling 2,906 shares during the quarter. Alps Advisors Inc.’s holdings in Y-mAbs Therapeutics were worth $148,000 as of its most recent filing with […] - 2025-07-18 04:50:54

Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $15.60

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, seven have issued a buy recommendation and two have issued a strong […] - 2025-07-07 02:43:05

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Holdings Trimmed by Millennium Management LLC

Millennium Management LLC trimmed its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 50.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 35,447 shares of the company’s stock after selling 36,139 shares during the period. Millennium Management LLC’s holdings […] - 2025-06-12 05:30:57

BNP Paribas Financial Markets Sells 21,545 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

BNP Paribas Financial Markets cut its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 81.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 4,874 shares of the company’s stock after selling 21,545 shares during the period. BNP Paribas Financial Markets’ holdings in Y-mAbs Therapeutics were worth $38,000 as of its most […] - 2025-06-05 04:28:49

ProShare Advisors LLC Acquires New Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

ProShare Advisors LLC acquired a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,645 shares of the company’s stock, valued at approximately $99,000. Several other institutional investors also recently […] - 2025-06-04 05:34:50

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Bought by Deutsche Bank AG

Deutsche Bank AG raised its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 52.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 32,253 shares of the company’s stock after purchasing an additional 11,059 shares during the quarter. Deutsche Bank AG’s holdings in Y-mAbs Therapeutics were worth $253,000 at the end of […] - 2025-06-02 04:42:52

HC Wainwright Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $11.00

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price objective dropped by investment analysts at HC Wainwright from $12.00 to $11.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 160.05% […] - 2025-05-21 02:42:45

Truist Financial Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $14.00

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price objective lowered by equities research analysts at Truist Financial from $18.00 to $14.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective suggests a potential upside of 262.69% […] - 2025-05-16 03:04:50

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong […] - 2025-05-15 03:10:49

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 3,070,000 shares, a decrease of 16.1% from the March 31st total of 3,660,000 shares. Based on an average daily volume of 400,200 shares, the short-interest ratio […] - 2025-05-05 02:35:05

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $18.30 Consensus Target Price from Brokerages

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating […] - 2025-04-23 02:46:51

32,256 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Purchased by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP bought a new stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) during the fourth quarter, HoldingsChannel reports. The fund bought 32,256 shares of the company’s stock, valued at approximately $253,000. Several other hedge funds and other institutional investors also recently bought and sold shares of YMAB. State Street Corp grew […] - 2025-04-14 04:46:52

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $18.00 by Analysts at Truist Financial

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its target price decreased by analysts at Truist Financial from $21.00 to $18.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price indicates a potential upside of 242.86% from the company’s previous close. YMAB has […] - 2025-03-07 04:30:47

Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $20.89

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have received an average recommendation of “Buy” from the ten brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating […] - 2025-03-04 04:35:15

Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $20.89

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have earned a consensus rating of “Buy” from the ten ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating on […] - 2025-02-07 04:49:03

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Position Boosted by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) by 10.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,335 shares of the company’s stock after purchasing an additional 2,854 shares during the quarter. JPMorgan Chase […] - 2025-01-30 06:59:08

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) YMAB holdings

Share Trades of YMAB by Blackrock for IE00BYXG2H39

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-09-10	BUY	182	8.580	8.590	8.589	USD 1,563	6.65
2025-09-05	SELL	-90	8.580	8.590	8.589	USD -773	6.63 Loss of -177 on sale
2025-08-29	SELL	-273	8.550	8.550	8.550	USD -2,334	6.59 Loss of -536 on sale
2025-08-27	BUY	180	8.550	8.560	8.559	USD 1,541	6.57
2025-08-26	SELL	-90	8.540	8.540	8.540	USD -769	6.56 Loss of -179 on sale
2025-08-25	BUY	90	8.520	8.540	8.538	USD 768	6.55
2025-08-20	SELL	-356	8.520	8.530	8.529	USD -3,036	6.53 Loss of -713 on sale
2025-08-18	BUY	178	8.520	8.535	8.533	USD 1,519	6.50
2025-08-08	SELL	-178	8.510	8.530	8.528	USD -1,518	6.45 Loss of -370 on sale
2025-08-06	BUY	90	8.520	8.520	8.520	USD 767	6.43
2025-08-01	SELL	-268	4.530	4.585	4.580	USD -1,227	6.44 Profit of 498 on sale
2025-07-30	BUY	356	4.790	5.180	5.141	USD 1,830	6.46
2025-07-17	SELL	-180	4.320	4.423	4.413	USD -794	6.56 Profit of 386 on sale
2025-07-16	BUY	6,355	4.350	4.390	4.386	USD 27,873	6.57
2025-07-11	SELL	-576	4.360	4.480	4.468	USD -2,574	6.61 Profit of 1,234 on sale
2025-07-07	BUY	216	4.220	4.330	4.319	USD 933	6.67
2025-07-02	BUY	3,960	4.260	4.570	4.539	USD 17,974	6.71
2025-06-25	BUY	142	4.910	5.240	5.207	USD 739	6.76
2025-06-11	BUY	142	4.930	5.190	5.164	USD 733	6.90
2025-06-10	BUY	142	5.110	5.285	5.267	USD 748	6.92
2025-06-04	SELL	-71	4.960	5.160	5.140	USD -365	6.97 Profit of 130 on sale
2025-04-23	BUY	71	4.120	4.400	4.372	USD 310	7.73
2025-04-10	SELL	-576	4.350	4.450	4.440	USD -2,557	8.00 Profit of 2,048 on sale
2025-04-08	SELL	-72	4.090	4.500	4.459	USD -321	8.07 Profit of 260 on sale
2025-04-07	SELL	-72	4.280	4.670	4.631	USD -333	8.11 Profit of 251 on sale
2025-04-04	SELL	-360	4.540	4.640	4.630	USD -1,667	8.15 Profit of 1,267 on sale
2025-04-01	BUY	288	4.500	4.515	4.513	USD 1,300	8.22
2025-03-31	SELL	-216	4.430	4.740	4.709	USD -1,017	8.26 Profit of 768 on sale
2025-03-14	SELL	-1,152	4.670	4.860	4.841	USD -5,577	8.72 Profit of 4,466 on sale
2025-03-07	SELL	-144	5.160	5.280	5.268	USD -759	8.97 Profit of 532 on sale
2025-03-04	SELL	-72	4.960	5.150	5.131	USD -369	9.13 Profit of 288 on sale
2025-02-25	BUY	144	5.580	5.780	5.760	USD 829	9.39
2025-02-19	SELL	-72	6.420	6.565	6.551	USD -472	9.60 Profit of 220 on sale
2025-02-13	BUY	216	6.170	6.390	6.368	USD 1,375	9.82
2025-02-12	BUY	72	5.930	5.940	5.939	USD 428	9.89
2025-02-11	BUY	288	5.770	6.210	6.166	USD 1,776	9.96
2025-01-17	BUY	288	6.160	6.320	6.304	USD 1,816	11.51
2025-01-16	BUY	288	6.180	6.550	6.513	USD 1,876	11.64
2025-01-10	SELL	-144	6.890	7.380	7.331	USD -1,056	12.19 Profit of 700 on sale
2025-01-08	SELL	-288	7.390	7.610	7.588	USD -2,185	12.47 Profit of 1,406 on sale
2024-12-30	SELL	-3,144	7.760	8.050	8.021	USD -25,218	12.75 Profit of 14,861 on sale
2024-11-18	SELL	-1,185	10.720	11.380	11.314	USD -13,407	14.81 Profit of 4,140 on sale
2024-11-08	SELL	-79	15.480	15.680	15.660	USD -1,237	14.88 Loss of -62 on sale
2024-10-21	SELL	-80	14.560	14.650	14.641	USD -1,171	0.00 Loss of -1,171 on sale

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of YMAB

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy